Filing a Drug Master File (MF) in Japan: PMDA Registration, Dossier Structure, and Lifecycle Control How to Register a Japan Master File: Scope, Dossier Craft, LOA, and Lifecycle Tactics Japan’s Master File (MF) at a Glance: Purpose, Benefits, and How It Differs from U.S./EU Systems Japan’s Master File (MF) system lets manufacturers register confidential chemistry, manufacturing, and controls (CMC) information with regulators so multiple product applications can reference the same technical package without exposing trade secrets to Marketing Authorization Holders (MAHs) or applicants. If you are familiar with a U.S. DMF or the EU’s CEP/ASMF, the concept will feel familiar—but…

Japan Re-Examination and Re-Evaluation: PMDA/MHLW Post-Marketing System for Approved Drugs Making Sense of Japan’s Re-Examination vs Re-Evaluation: What Sponsors Must Deliver After Approval Re-Examination vs Re-Evaluation in Japan: Purpose, Legal Foundations, and How They Diverge Japan operates two powerful post-marketing levers that every sponsor should plan for from day one of development: the re-examination system and the re-evaluation system. They sound similar but serve different policy goals. Re-examination is a time-bound, product-specific confirmation that a newly approved medicine maintains a favorable benefit–risk profile under real-world use. It functions as Japan’s data-exclusivity framework and as a structured evidence check on clinical…

Japan’s Pharmacovigilance System and GVP Implementation: A Practical Guide for MAHs and Global Safety Teams Making Pharmacovigilance Work in Japan: From GVP Rules to Real-World, PMDA-Ready Operations How Japan’s Pharmacovigilance Architecture Works: Laws, Roles, and the MAH’s End-to-End Accountability Japan’s pharmacovigilance (PV) framework is built on a tight weave of statute, ministerial ordinances, and operational guidance that make the Marketing Authorization Holder (MAH) unambiguously responsible for patient safety from launch through the full product lifecycle. Policy authority resides with the Ministry of Health, Labour and Welfare (MHLW), while scientific review, case intake infrastructure, and inspections are driven by the Pharmaceuticals…

Post-Approval Changes and Variations in Japan: PMDA/MHLW Requirements and ICH Q12 Strategies Managing Japan Post-Approval Changes: Variation Types, Evidence, and Lifecycle Control Variation Landscape in Japan: Legal Basis, Scope, and When a “Change” Becomes a “Variation” Post-approval change control in Japan is built on a dual structure: partial change approval (prior approval by the authority) and minor change notification (notification within a defined window). Policy authority sits with the Ministry of Health, Labour and Welfare, while scientific assessment and inspection coordination run through the Pharmaceuticals and Medical Devices Agency. The intent is simple: ensure that any alteration to quality, safety,…

PMDA Review Timelines and Fees Explained: A Sponsor’s Guide to Japan’s Clocks and Costs How Japan’s PMDA Clocks Run—and What You’ll Pay Along the Way The Review Clock in Japan: Where Timelines Begin, Pause, and End In Japan, review timing is both a science and a choreography. The legal authority that frames approvals and pricing sits with the Ministry of Health, Labour and Welfare (MHLW), while scientific assessment, dossier validation, and inspection coordination are handled by the Pharmaceuticals and Medical Devices Agency (PMDA). For sponsors, the practical question is: when does the clock start, when does it stop, and who…

Working with Japanese CROs and Local Regulatory Agents: Governance, CTN Workflows, and PMDA-Ready Execution Partnering in Japan: Managing CROs and Local Agents for Seamless PMDA Execution Why Japanese CROs and Local Agents Matter: Roles, Boundaries, and the Regulatory Context Japan is one of the world’s most exacting markets for medicines, and it rewards sponsors who respect both scientific rigor and local execution. Scientific assessment and inspections are led by the Pharmaceuticals and Medical Devices Agency (PMDA), while legal authority for approvals and policy rests with the Ministry of Health, Labour and Welfare (MHLW). In this framework, Japanese contract research organizations…

PMDA vs FDA Submission Requirements: Practical Differences Every Global Team Should Plan For How PMDA and FDA Diverge on Submissions—and What That Means for Your Plan Same ICH, Different Pathways: Governance and What “Japan Fitness” Really Means On paper, Japan and the United States share a deep ICH backbone (Q8–Q12 for quality, E-series for clinical, M4/eCTD). In practice, submission requirements diverge where each system operationalizes those principles. In Japan, scientific review and inspections are run by the Pharmaceuticals and Medical Devices Agency (PMDA), while policy and the ministerial decision sit with MHLW. In the U.S., both policy and scientific review…

Compliance with Japanese Medical Device Nomenclature (JMDN): Classification, Submissions, and Post-Market Control Getting JMDN Right in Japan: How to Classify, File, and Maintain Medical Devices What JMDN Is and Why It Matters in Japan’s Device Ecosystem Japanese Medical Device Nomenclature (JMDN) is Japan’s official taxonomy for medical devices and in vitro diagnostics (IVDs). It standardizes how products are named and grouped for classification, submission routing, labeling, and post-market controls. In practice, your JMDN selection influences whether a product follows Todokede (notification), Ninsho (pre-market certification via a Registered Certification Body), or Shonin (pre-market approval with agency review). It also frames the…

PMDA Consultations: Pre-Application Meetings, Briefing Book Strategy, and Decision-Ready Execution Winning PMDA Consultations: From Sharp Questions to Actionable, Japan-Ready Decisions What PMDA Consultations Are: Types, Timing, and Outcomes You Can Lock In In Japan, PMDA consultations are formal, fee-based scientific meetings that let you pressure-test strategy before filing. They are not casual Q&A sessions; they’re structured dialogues where assessors react to your plan and, crucially, record expectations in minutes that will anchor future reviews. Scientific assessment is led by the Pharmaceuticals and Medical Devices Agency, while ministerial policy and final approval decisions sit with the Ministry of Health, Labour and…

Risk Management Plans (RMP) in Japan: PMDA Expectations and Global Alignment with EU/US Building Japan-Ready RMPs that Align Seamlessly with EU and U.S. Systems What an RMP Means in Japan: Scope, Legal Context, and How It Differs From EU/US Paradigms In Japan, the Risk Management Plan (RMP) is the central, living document that translates a product’s risk profile into operable pharmacovigilance (PV) and risk-minimization measures that work in Japanese medical practice. Scientific review of the RMP sits with the Pharmaceuticals and Medical Devices Agency, while legal authority resides with the ministry. Together they enforce an integrated regime under GVP (safety…